ARS Pharmaceuticals Inc
NASDAQ:SPRY
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Price:
10.07
USD
2.86%
Market Closed
Market Cap:
$995.4m
Income Statement
Earnings Waterfall
ARS Pharmaceuticals Inc
ARS Pharmaceuticals Inc
Income Statement
ARS Pharmaceuticals Inc
ARS Pharmaceuticals Inc
Currency: USD
| Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1
N/A
|
1
+2%
|
1
+1%
|
1
N/A
|
0
-98%
|
0
-67%
|
1
+4 900%
|
3
+414%
|
89
+3 372%
|
97
+9%
|
112
+16%
|
143
+27%
|
|
| Gross Profit | ||||||||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(1)
|
(2)
|
(7)
|
(15)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
2
N/A
|
88
+4 413%
|
95
+7%
|
105
+11%
|
128
+21%
|
|
| Operating Income | ||||||||||||||||||||
| Operating Expenses |
(32)
|
(57)
|
(79)
|
(90)
|
(95)
|
(89)
|
(85)
|
(37)
|
(31)
|
(32)
|
(31)
|
(68)
|
(62)
|
(57)
|
(63)
|
(91)
|
(122)
|
(165)
|
(218)
|
|
| Selling, General & Administrative |
(11)
|
(18)
|
(25)
|
(28)
|
(29)
|
(30)
|
(33)
|
(18)
|
(27)
|
(33)
|
(37)
|
(47)
|
(43)
|
(39)
|
(43)
|
(72)
|
(105)
|
(150)
|
(206)
|
|
| Research & Development |
(21)
|
(39)
|
(54)
|
(62)
|
(66)
|
(59)
|
(52)
|
(18)
|
(20)
|
(16)
|
(11)
|
(20)
|
(19)
|
(19)
|
(20)
|
(20)
|
(17)
|
(14)
|
(13)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
16
|
17
|
17
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(32)
N/A
|
(57)
-77%
|
(79)
-40%
|
(90)
-13%
|
(95)
-6%
|
(89)
+6%
|
(85)
+5%
|
(36)
+58%
|
(30)
+17%
|
(30)
-3%
|
(29)
+3%
|
(68)
-130%
|
(62)
+8%
|
(57)
+8%
|
(61)
-7%
|
(3)
+95%
|
(27)
-778%
|
(59)
-119%
|
(91)
-53%
|
|
| Pre-Tax Income | ||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
1
|
2
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
(0)
|
(2)
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
5
|
8
|
11
|
13
|
12
|
12
|
11
|
11
|
12
|
12
|
11
|
|
| Pre-Tax Income |
(32)
N/A
|
(56)
-77%
|
(79)
-40%
|
(89)
-13%
|
(95)
-6%
|
(90)
+5%
|
(85)
+5%
|
(35)
+59%
|
(25)
+28%
|
(23)
+8%
|
(20)
+13%
|
(54)
-172%
|
(50)
+9%
|
(45)
+10%
|
(49)
-9%
|
8
N/A
|
(15)
N/A
|
(48)
-211%
|
(80)
-67%
|
|
| Net Income | ||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(32)
|
(56)
|
(79)
|
(89)
|
(95)
|
(90)
|
(85)
|
(35)
|
(25)
|
(23)
|
(20)
|
(54)
|
(50)
|
(45)
|
(49)
|
8
|
(16)
|
(48)
|
(80)
|
|
| Net Income (Common) |
(32)
N/A
|
(56)
-77%
|
(79)
-40%
|
(89)
-13%
|
(95)
-6%
|
(90)
+5%
|
(85)
+5%
|
(35)
+59%
|
(25)
+28%
|
(23)
+8%
|
(20)
+13%
|
(54)
-172%
|
(50)
+9%
|
(45)
+10%
|
(49)
-9%
|
8
N/A
|
(16)
N/A
|
(48)
-207%
|
(80)
-67%
|
|
| EPS (Diluted) |
-0.91
N/A
|
-1.61
-77%
|
-2.26
-40%
|
-2.56
-13%
|
-2.72
-6%
|
-2.57
+6%
|
-2.42
+6%
|
-0.87
+64%
|
-0.26
+70%
|
-0.24
+8%
|
-0.2
+17%
|
-0.57
-185%
|
-0.52
+9%
|
-0.47
+10%
|
-0.51
-9%
|
0.08
N/A
|
-0.15
N/A
|
-0.48
-220%
|
-0.81
-69%
|
|
Switch to:
Switch to:
See Also
Discover More
